Physician profile
Tabble B Memoli
NPI 1184976615
$1,143.23
in general payments reported to CMS, 2019-2025
16 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $353 · 2022: $70.84 · 2023: $227 · 2024: $261 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $719.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $213.95 | 2021-2024 | |
| Novo Nordisk INC | $152.51 | 2021-2023 | Wegovy |
| Lilly USA, LLC | $132.82 | 2021-2023 | Mounjaro |
| Viiv Healthcare Company | $125.00 | 2025 | Apretude |
| Amgen INC. | $106.00 | 2025 | Krystexxa |
| Neurocrine Biosciences, INC. | $99.37 | 2024 | Ingrezza |
| Biohaven Pharmaceuticals, INC. | $55.23 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $40.97 | 2021 | |
| Glaxosmithkline, LLC. | $39.16 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $36.52 | 2023 | Quviviq |
| Organon LLC | $30.71 | 2022-2023 | Nexplanon |
| Abbott Laboratories | $25.30 | 2023 | Freestyle Libre |
| Eisai INC. | $24.93 | 2021 | |
| Exact Sciences Corporation | $21.88 | 2023 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $19.57 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabble Memoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.